

A NEW ERA IN HEALTHCARE



FREE WRITING PROSPECTUS STATEMENT

This presentation of G Medical Innovations Ltd. (the "Company") highlights basic information about us and the offering to which this presentation relates. Because it is a summary, it does not contain all of the information that you should consider before investing in our securities. The Company has filed a Registration Statement (including a prospectus, which currently is in preliminary form) with the Securities and Exchange Commission ("SEC") for the offering to which this presentation relates. The Registration Statement has not yet become effective. Before you invest, you should read the Preliminary Prospectus in the Registration Statement (including the risk factors described therein) and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may access these documents for free by visiting EDGAR on the SEC web site at www.sec.gov. The Preliminary Prospectus, dated May 31, 2019, is available on the SEC web site at www.sec.gov/edgar. Alternatively, the Company or the underwriter participating in the offering will arrange to send you the Preliminary Prospectus and, when available, the final prospectus and/or any supplements thereto if you contact H.C. Wainwright & Co., LLC, at placements@hcwco.com or via telephone at 646-975-6996.



FORWARD LOOKING STATEMENTS

This presentation of the Company contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our objectives, plans, strategies, business model, next generation products, obtaining regulatory approvals, statements relating to the research, development, and use of our technologies and products. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's preliminary prospectus dated May 31, 2019, filed with the SEC as part of the Company's Registration Statement on Form F-1. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forwardlooking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.





G Medical Innovations is at the forefront of the digital health revolution in developing the next generation of mobile technologies that will empower consumers and providers to better monitor, manage, and improve clinical and personal health outcomes.

- Founded in 2014
- Public company, traded on the ASX (GMV)
- Global Presence
- 100 Employees worldwide
- 1. Australia Holding Company
- 2. Israel R&D and Regulatory
- 3. USA Remote patient monitoring services and selling of medical devices
- 4. China Production, local sales and marketing
- 5. Macedonia Additional R&D
- 6. UK Remote patient monitoring services
- 7. Hong Kong Business sales hub





THE COMPANY'S VISION

G Medical Innovations seeks to usher in a new era of healthcare and wellness by utilizing its patented wireless technologies, and proprietary information technology and service platforms, to empower a new generation of consumers, patients and providers to improve quality of life by:





G MEDICAL – WINNING WITH EXPERIENCE



Strong R&D

 Over 25 years of experience in developing mobile embedded medical sensors



Regulatory approvals

- Medical grade devices cleared following FDA and CE guidance
- Team experience obtaining clearance with the FDA for over 48 medical devices



Go To Market

 Over 25 years of medical device development and commercialization



Medical Service Model – Medical Call Centers setup and operation

- Over 25 years of experience in international and US patients monitoring
- Over 5M patients monitored



MANAGEMENT TEAM

Established track record in commercialising medical devices

Dr. Yacov Geva

President & CEO

Dr. Geva is a well-known pioneer in the industry of Medical Devices and remote monitoring services, and co-founder of LifeWatch AG (former Card Guard AG and Card Guard Scientific Survival Ltd.). Successfully led LifeWatch to an IPO. Dr. Geva holds a B.Sc in Mechanical and Nuclear Engineering, a Ph.D. (with honors) in Business Administration from the International School of Management, Paris and an honorary doctorate from Oxford Brooks University. Dr. Geva is also a senior member of the royal society of medicine in the UK (RSM).

Mr. Rafi Heumann

President & COO

Mr. Heumann has over 20 years of experience in Hi-tech, mHealth, operations and services industries. He brings with him advanced skills in strategic planning, international negotiations and business development, and directing complex projects. Mr. Heumann has business management education from Bar-Ilan University, Israel.

Mr. Kobi Ben-Efraim

CFO

Mr. Ben-Efraim is an experienced and senior CFO of global companies with more than 20 years' experience in the finance and accounting domain. He has served in Israeli high tech companies including DSPC Group (a NASDAQ-traded company) and EI-Op. Mr. Ben-Efraim holds a B.A. in Economics and Accounting from Tel Aviv University, and is a Certified Public Accountant (IL).

Mr. Oded Shahar

Senior Vice President Mergers and Acquisitions

Mr. Shahar is serving as our Senior Vice President Mergers and Acquisitions since July, 2017. From August 2004 to November 2007, Mr. Shahar served as the head of the Israeli branch of Crédit Agricole Corporate and Investment Bank. Since 2007, Mr. Shahar has managed his own law firm, specializing in banking and international investments, mergers & acquisitions and international contracts. Mr. Shahar holds an LL.B. from Tel Aviv University, is qualified as a Notary and is a member of the Israel Bar Association.

Mr. Benny Tal

VP, R&D

Mr. Tal brings over 40 years of expertise in Electronics Development, Engineering and Operations. He has led R&D, engineering, and operation teams for OEM/ODM products. Mr. Tal holds a B.Sc.in Electrical Engineering and Computers and an MBA from Ben-Gurion University, Israel.

Mr. Nir Geva

CTO & Business Development

Mr. Geva has over 17 years of experience in the Hi-Tech and Medical Device industry. A former CTO and strategic projects manager at LifeWatch Technologies, he has broad knowledge on project management and manufacturing of medical devices. Mr. Geva wrote over 15 patents related to Medical Devices, Remote Patients Monitoring and IoT. He holds a BSc. in Mechanical Engineering from the Technion in Haifa and an Executive MBA from Kellogg school of management, (Northwestern University in Chicago).



BOARD OF DIRECTORS

Diverse international Board, with expertise in growth companies

Dr. Kenneth R. Melani

Chairman of the Board

Dr. Melani has over 30 years' experience in the healthcare industry as a provider, supplier and insurer. He has started seven successful for-profit health services businesses and has served in various critical business roles including CEO, Chief Medical Office, and Strategy and Business Development.

During his tenure as President and CEO of Highmark Inc. in 2003 to 2012, he grew the company into one of the largest and most diversified healthcare companies in the United States, serving over 32 million individuals. He has been an investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

Dr. Shuki Gleitman

Non Executive Director

Dr. Gleitman is the Chairman of the Guangzhuo Israel Biotech Fund, Chairman of the Board of Directors of Capital Point Group, a Board member and Chairman of the audit and financial committees of Elbit Systems (NASDAQ, TLV traded), Chairman of the YoYa Group, Senior Advisor to the World Bank (national policy for innovation) and Senior Strategy Advisor to Serbia Innovation Fund. Prior to this, Dr. Gleitman was the Chief Scientist and Director General of Israel's Ministry of Industry and Trade, where he managed all of the Israeli Government technological programs.

Dr. Yacov Geva

President & CEO Executive Director

.Prof. Zeev Rotstein, Director

Non Executive Director

Prof. Rotstein has served on our board of directors since March 2019, Prof. Rotstein has served as the director general of Hadassah Medical Organization since February 2016, and as an Associate Clinical Professor at the Hebrew University of Jerusalem and the Sackler School of Medicine Tel Aviv University. Professor Rostein has acted as an expert consultant in the construction of several medical facilities throughout the world including Centro Medico La Paz, Equatorial Guinea (major referral hospital in Equatorial Guinea), the Lagoon Hospital, Accra, Ghana and currently the Moscow Medical Cluster Oncological Centre and During his extensive Polyclinic of Skolkovo, Moscow career. Prof. Rotstein served as treasurer at the State's Physician Organization, chairman of the World Fellowship of the Israel Medical Association (I.M.A.), and member of the Editorial Board of Associations des Médécins Israelites de France, Prof. Rotstein served as a committee member of the I.M.A. Scientific Committee. Prof. Rotstein holds a Ph.D. in Cardiology from the Sackler School of Medicine at the Tel-Aviv University, and an M.B.A (cum laude) from the Leon Recanati Graduate School of Business Administration at the Tel-Aviv University, and has held fellowships at the New York Department of Health, Tufts University, and Johns Hopkins Medical Centre School of Hygiene and Public Health.

Mr. Urs Wettstein

Non Executive Director

Mr Wettstein has an accounting, auditing and taxation background in Switzerland, having founded his own accounting firm and also worked with Coopers and Lybrand AG in Zurich. He has been an advisor and investor in numerous pre- IPO investments since 1985 and was instrumental for several successful IPOs in Switzerland.

Dr. Brendan de Kauwe

Non Executive Director

Dr de Kauwe studied a Bachelor of Science and Bachelor of Dental Surgery from the University of Western Australia, and also holds a Post Graduate Diploma in Applied Finance, majoring in Corporate Finance. He is an ASIC complaint (RG146) Securities Advisor. Dr de Kauwe's is a Director of Otsana Capital, an Investment Banking firm, with significant experience in corporate restructuring and recapitalisations, mergers and acquisitions, IPO and Reverse Merger transactions and equity capital markets. He has been the Chairman and Director of numerous ASX Listed Companies, and is currently Director of Ookami Ltd (ASX:OOK).

2

THE MARKET



THE GLOBAL HEALTHCARE CHALLENGE

Rising complexity and cost

Healthcare spending as % of GDP is increasing:

USA: 17% and rising

• OECD: 9% and rising

EU: 10% and rising

As patients become more demanding and providers' constraints more challenging, cost-effective health solutions and access become a top priority

mHealth provides answers to major healthcare challenges:

- Improved productivity and efficiency
- Better utilisation of centralised assets and scarce talent resources



PATIENTS

Aging, more self-guided, more obese, suffering from increasingly complex and chronic diseases



PROVIDERS

Rising treatment costs, shortage of talent, growing capacity and budget constraints



PAYERS

Increasing pressure to provide quality of care and contain costs



GOVERNMENT

Increasing access to care, pressure to provide cost-effective, high-quality outcomes

Source: World Bank, OECD, European Commission

.



Mobile Health solutions promise better care and lower costs

Centralized assets and competencies



Patients

- Quality
- Convenience
- Cost

Remote access to healthcare services – addressing the talent shortage



Providers

- Quality and efficiency
- Referrals and retention
- Add-on services

Standardized, assisted, selfsupported care provisioning



Payers

Quality

Risk reduction

Cost efficiencies

Overall productivity, quality, and convenience gains




Government

Quality

Universal access

ESTIMATED POSITIVE IMPACT OF M-HEALTH ON KEY HEALTH CARE COST DRIVERS:




Source: Research2Guidance



MARKET SIZING

Fast growth and adoption of mHealth solutions


Global mHealth market revenues




<u>IoT devices in healthcare</u>



Physicians offering services via mobile devices




Health insurance providers paying for services via mobile devices






THE OPPORTUNITY - mHEALTH MARKET


The global mHealth enabled care market was worth \$17.2 Billion in 2016




Source: Prost & Sullivan, Clinical mHealth Growth Opportunities, June 2016

Bulk of the global revenues come from services for diagnostic, monitoring, chronic disease management, and antiquated applications. The fastest growing segments have been mobile tools and healthcare apps, which have grown at 26% and 14% compound annual growth rate (CAGR) respectively between 2013 to 2016.











PRIZMA **SENSORS**

Simply place the Prizma sensors on your smartphone and start taking tests



PRIZMA **MEDICAL APP**

The Prizma app is always with you on your smartphone. You can download it from the Apple App Store™ and Google Play™



USERS PORTAL

Easily view and share your medical test results and history







COMPLETE SOLUTION








PRODUCT FUNCTIONALITY





PERSONAL MEDICAL "USER" PORTAL

Contains Prizma test results, and trending charts
Navigate to user settings, testing tutorials and support, set test reminders






PERSONAL MEDICAL "DOCTOR" PORTAL

Doctor's Dashboard

Contains Abnormal Test Results, Medical History; Prizma test results; Call History; Physician comments





PRIZMA REPORT

Share your results with any third party from your phone or user portal






VSMS patch - Extended Holter System, up to 14 days

Continuously (beat to beat) records a multi-channel (6 leads) ECG and saves the waveforms to SD card. At the end of the service an extended ambulatory report is provided directly to the physician.

Lead I, lead II, lead III, aVL, aVF, and aVR



- Single device with comfortable format enhances patient compliance – no wires or extra equipment
- Comfortable wearable format increases diagnostic yields
- IP (or "Ingress Protection") rating allows daily showering
- Manual "event" button allows patient to mark a suspected cardiac event.





G MEDICAL PRIZMA – CURRENT & NEXT GENERATION

EXPANDING VITAL AND BIOMETRIC MONITORING CAPABILITIES



^{*} Stress analysis is a non-medical test added to the Prizma as a wellness application.

^{**} Blood pressure, weight and glucose can be measured by other devices, and the data can be integrated manually or via Bluetooth to our Prizma App so additional medical parameters can be saved in the User Portal.

4

BUSINESS MODEL



PRIZMA

Sales of Products

Prizma & Accessories

Services Fee Income





Cloud \ Portal (CMS) Chronic Care Management



Call Center

Channels

B2B

- **Insurance Companies**
- **Medical Institutions**
- Other Distributors

B2C

- Online Store
- **Market Places**

VSMS/GMP

Services Income

Per Patient Use

Sales of Products

- Patch Unit
- Disposables
- System

Channels

B2B

- Hospitals & Clinics
- Home Monitoring

SYNERGY

PRE- HOSPITALIZATION

HOSPITALIZATION

POST-DISCHARGE

PATIENTS' HEALTHCARE LIFECYCLE





IDTF USA BUSINESS MODEL

THE PROCESS















Patient enrolled on service

Insurance coverage verified

Patient monitored for up to 30 days

24/7 Live Patient Support Urgent / daily reports sent to Physician

Summary Report posted

Patient returns device

INCOME BASED ON SERVICE TYPE

Extended Holter (14 days)


External Mobile Cardiovascular Telemetry (MCOT)

Cardiac Event Monitoring



AMBULATORY CARDIAC MONITORING OFFERS SIGNIFICANT OPPORTUNITY

Increased diagnostic yield leads to timely diagnosis




Measure	Product Type	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	CAGR ('15-'25)
Market Value (USDM)	Holter Monitors	169	197	231	270	312	355	397	438	476	511	543	12.4%
	Event Recorders	321	321	319	316	311	307	302	299	297	297	298	-0.8%
	Telemet ry Devices	282	399	542	701	864	1,020	1,166	1,300	1,421	1,528	1,625	19.1%
	ILRs	236	273	313	366	437	549	711	796	865	920	963	15.1%
	Total	1,008	1,190	1,405	1,653	1,924	2,231	2,577	2,834	3,059	3,256	3,429	13.0%
Market Value (% Growth)	Holter Monitors	_	16.8%	17.3%	16.9%	15.5%	13.7%	11.9%	10.2%	8.7%	7.4%	6.3%	12.4%
	Event Recorders	_	0.0%	-0.6%	-1.0%	-1.4%	-1.5%	-1.4%	-1.0%	-0.7%	-0.2%	0.3%	-0.8%
	Telemet ry Devices	_	41.5%	35.7%	29.4%	23.2%	18.1%	14.3%	11.5%	9.3%	7.6%	6.3%	19.1%
	ILRs	_	15.6%	14.6%	17.1%	19.4%	25.6%	29.6%	12.0%	8.6%	6.3%	4.7%	15.1%
	Total	_	18.1%	18.0%	17.7%	16.4%	15.9%	15.5%	10.0%	8.0%	6.4%	5.3%	13.0%

Source: Ambulatory Electrocardiography Monitoring Devices | Market Analysis | US | 2017, Decision Resources Group



U.S.A. TELEMETRY DEVICE MARKET (USD) 2015–2025



5

MILESTONES




INVESTMENTS / IPO



Source: Management



REGULATIONS



Source: Management



THANK YOU